Logo of Bubs Australia (ASX:BUB)Latest Bubs Australia (ASX:BUB) News

Page 1
Page 1 of 2

Bubs reaches 12,000 US stores as revenue falls and cash burn rises

Bubs Australia has expanded its US footprint to more than 12,000 stores after securing permanent FDA authorisation, but quarterly revenue fell 9.8% and operating cash outflow increased. The company ended September with A$13.4 million of available liquidity, equivalent to 2.2 quarters at the reported cash-burn rate.
Victor Sage
29 Oct 2026

Market Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Small-cap shares swung widely as exploration results, takeover bids and funding needs drove the week’s biggest moves.
Kaoko plunged while PARKD rallied, showing how quickly thinly traded stocks can change direction.
Logan Eniac
17 Oct 2026

Bubs posts EBITDA recovery as FDA approval meets a $15.1 million cash drain

Bubs Australia delivered 9.2% revenue growth and a sharp underlying EBITDA improvement in FY26, but statutory losses, weaker margins and negative operating cash flow expose the cost of its expansion. Permanent US FDA authorisation removes a major regulatory hurdle, while the annual report still flags material uncertainty around ongoing funding and cash generation.
Victor Sage
14 Oct 2026

Market Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Rare earths, scandium and biotech stocks led the week’s gains, while a rights issue sent Green & Gold Minerals sharply lower. Large capital raisings, mine funding and takeover activity kept resources at the centre of investor attention.
Logan Eniac
12 Sept 2026

Bubs Secures Permanent FDA Approval for Three Infant Formula Products

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
10 Sept 2026

Bubs Australia Flags FY26 Revenue $105M-$115M Amid Supply and Geopolitical Headwinds

Bubs Australia expects FY26 revenue between $105 million and $115 million, with underlying EBITDA forecast at $4 million to $8 million despite external challenges including regulatory delays and increased air freight costs.
Victor Sage
29 May 2026

Bubs Australia Surges on US Growth, Lifts FY26 Earnings Outlook

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.
Victor Sage
27 Feb 2026

Bubs Australia’s US Surge Drives 14% Revenue Rise in H1 FY26

Bubs Australia reports a 14% increase in half-year revenue, powered by a 47% jump in US sales, while other regions face challenges. The company remains optimistic about FDA approval and market recovery in H2 FY26.
Victor Sage
30 Jan 2026

Bubs Australia Eyes 27% Growth Amid Strategic Overhaul and Market Expansion

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.
Victor Sage
20 Nov 2025

Bubs Australia Secures $825K Recovery Amid Legal Dispute Closure

Bubs Australia Limited announces it expects to recover A$825,000 from Willis Trading Limited’s secured creditor following arbitration proceedings, while no further recoveries are anticipated from related parties.
Victor Sage
6 Nov 2025

Bubs Australia Boosts Revenue 30% with Strong US Growth and Positive EBITDA

Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.
Victor Sage
31 Oct 2025

Bubs Australia Elevates Paul Jensen to Chair, Welcomes Joe Coote as CEO

Bubs Australia has appointed Paul Jensen as its new Independent Chair and Joe Coote as Managing Director and CEO, signaling a fresh leadership chapter for the infant formula and dairy company.
Victor Sage
15 Sept 2025